Literature DB >> 15193950

The role of C-reactive protein in ischemia/reperfusion injury and preconditioning in a rat model of myocardial infarction.

A Valtchanova-Matchouganska1, M Gondwe, A Nadar.   

Abstract

For the first time the involvement of C-Reactive protein (CRP) in early (acute) and delayed ischemic (IPC) and pharmacological (chemical) preconditioning (CPC) in an in vivo model of rat myocardial infarction was presented. Acute IPC was produced by three 5 minute occlusion (ischemia) periods interspersed with 5 minute reperfusion, followed by 30 minute occlusion of the left coronary artery and 2 hour reperfusion injury. Acute CPC was produced by a k-opioid receptor agonist U50488H (5 mg/kg) applied i.v. 15 minutes before 30 minute ischemia/ 2 hour reperfusion. Delayed preconditioning was produced by 30 minute ischemia/ 2 hour reperfusion, induced 24 hour after either ischemic or pharmacological preconditioning. The myocardial ischemia/reperfusion injury was evaluated on the basis of total and cardiac creatine kinase isoenzyme activity, functional recovery of the heart (ECG), infarct size (% IS/RA) and mortality at the end of the experiments. The results obtained showed that: k-opioid receptor agonist U50488H mimics both the acute and delayed IPC in the above experimental protocol; Both acute IPC and most probably CPC act by opening of K(ATP) channels (the effects were blocked by nonspecific ATP-sensitive K channel blocker glybenclamide), and via activation of protein kinase C (a selective protein kinase C inhibitor chelerythrine blocked the efects); C-reactive protein (CRP) was significantly elevated by 54% in non-preconditioned acute ischemia/reperfusion injury. The elevation was more pronounced (82% increase) 24 hour after non-preconditioned ischemia/reperfusion injury. It reflected very well the increase in cardiac isoenzymes, infarct size and mortality of the rats, and can be used as a marker of the severity of myocardial injury in this model; The increase of CRP was prevented by both IPC and CPC in early, and especially in late preconditioning. This confirms the involvement of CRP as a marker in cardiac ischemic/reperfusion injury. It was concluded that in addition to the established involvement of adenosine, bradykinin, opioid and other receptors, a suppression of myocardial CRP/complement production might be involved in the biological mechanism of preconditioning. This could be a promising perspective in clinical interventions against ischemia/reperfusion injuries of the heart.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15193950     DOI: 10.1016/j.lfs.2003.12.029

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  10 in total

1.  Resveratrol pretreatment protects rat hearts from ischemia/reperfusion injury partly via a NALP3 inflammasome pathway.

Authors:  Wusong Dong; Rui Yang; Jian Yang; Jun Yang; Jiawang Ding; Hui Wu; Jing Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

2.  Is There a Role for Bioactive Lipids in the Pathobiology of Diabetes Mellitus?

Authors:  Undurti N Das
Journal:  Front Endocrinol (Lausanne)       Date:  2017-08-02       Impact factor: 5.555

3.  Rat experimental model of myocardial ischemia/reperfusion injury: an ethical approach to set up the analgesic management of acute post-surgical pain.

Authors:  Maria Chiara Ciuffreda; Valerio Tolva; Renato Casana; Massimiliano Gnecchi; Emilio Vanoli; Carla Spazzolini; John Roughan; Laura Calvillo
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

4.  Cardioprotective role of insulin: Advantage analogues.

Authors:  Rituparna Maiti; Jyothirmai Jaida; Pulukuri John Israel Leander; Mohammed Irfanuddin; Idris Ahmed; Anuradha Palani
Journal:  J Res Med Sci       Date:  2012-07       Impact factor: 1.852

5.  Prevention of postoperative atrial fibrillation: novel and safe strategy based on the modulation of the antioxidant system.

Authors:  Ramón Rodrigo
Journal:  Front Physiol       Date:  2012-04-12       Impact factor: 4.566

Review 6.  Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons.

Authors:  Jan Torzewski; Patrizia Brunner; Wolfgang Ries; Christoph D Garlichs; Stefan Kayser; Franz Heigl; Ahmed Sheriff
Journal:  J Clin Med       Date:  2022-03-23       Impact factor: 4.241

Review 7.  Molecular basis of cardioprotective effect of antioxidant vitamins in myocardial infarction.

Authors:  Ramón Rodrigo; Matías Libuy; Felipe Feliú; Daniel Hasson
Journal:  Biomed Res Int       Date:  2013-07-14       Impact factor: 3.411

8.  C-reactive protein aggravates myocardial ischemia/reperfusion injury through activation of extracellular-signal-regulated kinase 1/2.

Authors:  Wei-Na Pei; Hai-Juan Hu; Fan Liu; Bing Xiao; Ya-Bei Zuo; Wei Cui
Journal:  J Geriatr Cardiol       Date:  2018-07       Impact factor: 3.327

Review 9.  Selective Apheresis of C-Reactive Protein for Treatment of Indications with Elevated CRP Concentrations.

Authors:  Stefan Kayser; Patrizia Brunner; Katharina Althaus; Johannes Dorst; Ahmed Sheriff
Journal:  J Clin Med       Date:  2020-09-12       Impact factor: 4.241

Review 10.  [CRP apheresis in acute myocardial infarction and COVID-19].

Authors:  Michael Buerke; Ahmed Sheriff; Christoph D Garlichs
Journal:  Med Klin Intensivmed Notfmed       Date:  2022-03-25       Impact factor: 1.552

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.